Compare KAI & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KAI | IDYA |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 1996 | 2019 |
| Metric | KAI | IDYA |
|---|---|---|
| Price | $323.70 | $34.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $337.50 | $51.21 |
| AVG Volume (30 Days) | 169.5K | ★ 795.5K |
| Earning Date | 05-26-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,052,248,000.00 | $218,710,000.00 |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $4.87 | $213.03 |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $244.87 | $13.45 |
| 52 Week High | $374.20 | $39.28 |
| Indicator | KAI | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 57.98 |
| Support Level | $317.17 | $32.85 |
| Resistance Level | $346.77 | $37.08 |
| Average True Range (ATR) | 17.00 | 1.35 |
| MACD | -1.99 | 0.35 |
| Stochastic Oscillator | 44.68 | 80.99 |
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.